Biotechnology company Tenaya Therapeutics Inc (NASDAQ:TNYA) reported on Monday the addition of June Lee, MD, to its board of directors.
The company added that JJ Kang, PhD will resign from board after five years of service to focus on her current role as CEO of Appia Bio and Venture Partner at The Column Group. Dr Kang has served as the company's board member 2016 as well as interim president for two years.
More recently, Dr Lee was the founder and CEO of Esker Therapeutics as well as executive vice president, chief development officer and chief operating officer of MyoKardia.
Previously, Dr Lee was the therapeutic area head for early clinical development in cardiovascular, metabolism, respiratory and infectious diseases at Genentech.
Currently, Dr Lee is a member of the Advisory Board for Johns Hopkins University Center for Therapeutic Translation, board of director for Eledon Pharmaceuticals Inc and GenEdit, as well as the Scientific Advisory Board for Foresite Labs, respectively.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial